Progress in the development of specific immunotherapies for house dust mite allergies

Expert Review of Vaccines

Volumn 13, Issue 12, 2014, Pages 1463-1473

  Moingeon, Philippe ^a  

^a Stallergenes SA   (France)

Author keywords

Allergen; Dermatophagoides; House dust mite; Immunotherapy; Vaccine

Indexed keywords

HOUSE DUST ALLERGEN; RECOMBINANT ALLERGEN; ALLERGEN; RECOMBINANT PROTEIN;

ALLERGIC RHINITIS; CLINICAL STUDY; DERMATOPHAGOIDES; DERMATOPHAGOIDES FARINAE; DERMATOPHAGOIDES PTERONYSSINUS; HOUSE DUST ALLERGY; HUMAN; IMMUNOTHERAPY; NONHUMAN; REVIEW; SENSITIZATION; SUBCUTANEOUS IMMUNOTHERAPY; SUBLINGUAL IMMUNOTHERAPY; ADVERSE EFFECTS; ANIMAL; ASTHMA; DESENSITIZATION; DRUG DEVELOPMENT; HYPERSENSITIVITY; IMMUNOLOGY; PROCEDURES; PYROGLYPHIDAE; RHINITIS; SUBCUTANEOUS DRUG ADMINISTRATION; SUBLINGUAL DRUG ADMINISTRATION; TREATMENT OUTCOME; TRENDS;

ADMINISTRATION, SUBLINGUAL; ALLERGENS; ANIMALS; ASTHMA; DERMATOPHAGOIDES FARINAE; DERMATOPHAGOIDES PTERONYSSINUS; DESENSITIZATION, IMMUNOLOGIC; DRUG DISCOVERY; HUMANS; HYPERSENSITIVITY; INJECTIONS, SUBCUTANEOUS; PYROGLYPHIDAE; RECOMBINANT PROTEINS; RHINITIS; TREATMENT OUTCOME;

EID: 84909580267     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/14760584.2014.948861     Document Type: Review

References (88)

1. Bousquet J, Khaltaev N, Cruz AA, et al. Allergic rhinitis and its impact on asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy 2008;63(Suppl 86):8-160
2. Van Bronswijk JE, Sinha RN. Pyroglyphid mites (Acari) and house dust mite allergy. J Allergy 1971;47:31-52
3. Thomas WR. Geography of house dust mite allergens. Asian Pac J Allergy Immunol 2010;28:211-24
4. Hales BJ, Martin AC, Pearce LJ, et al. IgE and IgG anti-house dust mite specificities in allergic disease. J Allergy Clin Immunol 2006;118:361-7
5. Weghofer M, Thomas WR, Kronqvist M, et al. Variability of IgE reactivity profiles among European mite allergic patients. Eur J Clin Invest 2008;38:959-65
6. Barber D, Arias J, Boquete M, et al. Analysis of mite allergic patients in a diverse territory by improved diagnostic tools. Clin Exp Allergy 2012;42:1129-38
7. Voorhorst R, Spieksma F, Varekamp H, et al. The house dust mite (Dermatophagoides pteronyssinus) and the allergens it produces. Identity with the house dust allergen. J Allergy 1967;39: 323-39
8. Miyazawa H, Sakaguchi M, Inouye S, et al. Seasonal changes in mite allergen (Der pI and Der pII) concentrations in Japanese homes. Ann Allergy Asthma Immunol 1996;76:170-4
9. Moscato G, Perfeti L, Galdi E, et al. Levels of house-dust-mite allergen in homes of nonallergic people in Pavia, Italy. Allergy 2000;55:873-8
10. Ngelhart S, Bieber T, Exner M. House dust mite allergen levels in German day-care centers. Int J Hyg Environ Health 2002;205:453-7
11. Sidenius KE, Hallas TE, Poulsen LK, Mosbech H. House dust mites and their allergens in Danish mattresses - results from a population based study. Ann Agric Environ Med 2002;9:33-9
12. Raffan E, Lawrence H, Henderson T, et al. Prevalence of the group 1 Dermatophagoides allergens Der p 1 and Der f 1 in homes with no dogs, healthy dogs and Dermatophagoides-sensitized atopic dogs in Liverpool. Vet Dermatol 2005;16:253-60
13. Macchiaverni P, Rekima A, Turfkruyer M, et al. Respiratory allergens in human milk: potential impact on susceptibility to allergic asthma. Allergy 2014;69:395-8
14. Schram-Bijkerk D, Doekes G, Boeve M, et al. Nonlinear relations between house dust mite allergen levels and mite sensitization in farm and non-farm children. Allergy 2006;61:640-7
15. Zock JP, Heinrich J, Jarvis D, et al. Distribution and determinants of house dust mite allergens in Europe: the European Community Respiratory Health Survey II. J Allergy Clin Immunol 2006;118:682-90
16. Smith AM, Benjamin DC, Hozic N, et al. The molecular basis of antigenic cross reactivity between group 2 mite allergens. J Allergy Clin Immunol 2001;107:977-84
17. Park JW, Kim KS, Jin HS, et al. Der p 2 isoallergens have different allergenicity and quantification with 2-site ELISA using monoclonal antibodies is influenced by the isoallergens. Clin Exp Allergy 2002;32: 1042-7
18. Hales BJ, Thomas WR. T cell sensitization to epitopes from the house dust mites Dermatophagoides pteronyssinus and Euroglyphus maynei. Clin Exp Allergy 1997;27:266-875
19. Hales BJ, Shen HD, Thomas WR. Cross reactivity of T cell responses to Dermotophagoides pteronyssinus and D. farinae: studies with group 1 and 7 allergens. Clin Exp Allergy 2000;30:927-33
20. Wambre E, Bonvalet M, Bodo VB, et al. Distinct characteristics of seasonal (Bet v 1) vs. perennial (Der p 1/Der p 2) allergen-specific CD4+ T cell responses. Clin Exp Allergy 2010;41:192-203
21. Gregory LG, Lloyd CM. Orchestrating house dust mite-associated allergy in the lung. Trends Immunol 2011;32:402-11
22. Jacquet A. Innate immune responses in house dust mite allergy. IRSN Allergy 2013;2013:1-18.735031 Hindoui publishing Ed
23. Hammad H, Lambrecht B. Dendritic cells and epithelial cells: linking innate and adaptive immunity in asthma. Nat Rev Immunol 2008;8:193-204
24. Hammad H, Chieppa M, Perros F, et al. House dust mite allergen induces asthma via TLR4 triggering of airway structural cells. Nat Med 2009;15:410-16
25. Valerio RC, Murray P, Arlian LG, Slater JE. Bacterial 16S ribosomal DNA in house dust mite cultures. J Allergy Clin Immunol 2006;118:1296-300
26. Da Silva CA, Pochard P, Lee CG, Elias JA. Chitin particles are multifaceted immune adjuvants. Am J Respir Crit Care Med 2010;182:1482-91
27. Thomas WR, Smith W, Hales BJ. The allergenic specificities of the house dust mite. Chang Gung Med J 2004;27:563-9
28. Thomas WR, Hales BJ, Smith WA. House dust mite allergens in asthma and allergy. Trends Mol Med 2010;16:321-8
29. Bessot JC, Pouli G. Mite allergens: an overview. Eur Annu Allergy Clin Immunol 2011;43:141-56
30. WHO/IUIS allergen nomenclature database. Available from: www.allergen.org
31. Batard T, Nony E, Chabre H, et al. Molecular and functional characterization of natural allergen extracts. Proceedings of the 13th PEI meeting (14-17 September 2011). 2013. pp 54-6
32. Zhang YY, Sun X, Liu ZG. Morphology and Three-dimensional reconstruction of the digestive system of dermatophagoides farinae. Int Arch Allergy Immunol 2008;146:219-26
33. Batard T, Hrabina A, Bi XZ, et al. Production and proteomic characterization of pharmaceutical grade Dermatophagoides pteronyssinus and Dermatophagoides farinae extracts for allergy vaccines. Int Arch Allergy Immunol 2006;140:295-305
34. Weghofer M, Grote M, Resch Y, et al. Identification of Der p 23, a peritrophin-like protein, as a new major Dermatophagoides pteronyssinus allergen associated with the peritrophic matrix of mite fecal pellets. J Immunol 2013;190:3059-67
35. Hales BJ, Elliot CE, Chai LY, et al. Quantification of IgE binding to the Chitinase and Chitinase-like house dust mite allergens Der p 15 and Der p 18 compared to the major and mid range allergens. Int Arch Allergy Immunol 2013;160:233-40
36. Kidon M, Chin CW, Kong LW, et al. Mite component-specific IgE repertoire and phenotypes of allergic disease in childhood: the tropical perspective. Pediatr Allergy Immunol 2011;22:202-10
37. Chapman MD, Wunschmann S, Pomes A. Proteases as Th2 adjuvants. Curr Allergy Asthma Rep 2007;7:363-7
38. Roelandt T, Heughebaert C, Hachem JP. Proteolytically active allergens cause barrier breakdown. J Invest Dermatol 2008;128:1878-80
39. Trompette A, Divanovic S, Visintin A, et al. Allergenicity resulting from functional mimicry of a Toll-like receptor complex protein. Nature 2009;457:585-8
40. Mueller GA, Edwards LL, Aloor JJ, et al. The structure of the dust mite allergen Der p 7 reveals similarities to innate immune proteins. J Allergy Clin Immunol 2010;125:909-17
41. Epton MJ, Dilworth RJ, Smith W, Thomas WR. Sensitization to the lipid-binding apolipophorin allergen Der p 14 and the peptide Mag-1. Int Arch Allergy Immunol 2001;124:57-60
42. Smith WA, Hales BJ, Jarnicki AG, Thomas WR. Allergens of wild house dust mites: environmental Der p 1 and Der p 2 sequence polymorphisms. J Allergy Clin Immunol 2001;107:985-92
43. Ayuso R, Reese G, Leong-Kee S, et al. Molecular basis of arthropod cross-reactivity: igE-binding cross-reactive epitopes of shrimp, house dust mite and cockroach tropomyosins. Int Arch Allergy Immunol 2002;129:38-48
44. Van Ree R, Antonicelli L, Akkerdaas JH, et al. Possible induction of food allergy during mite immunotherapy. Allergy 1996;51:108-13
45. Pajno GB, La Grutta S, Barberio G, et al. Harmful effect of immunotherapy in children with combined snail and mite allergy. J Allergy Clin Immunol 2002;109:627-9
46. Tourdot S, Airouche S, Berjont N, et al. Evaluation of therapeutic sublingual vaccines in a murine model of chronic house dust mite allergic airway inflammation. Clin Exp Allergy 2011;41:1784-92
47. Passalacqua G, Durham SR. Allergic rhinitis and its impact on asthma update: allergen immunotherapy. J Allergy Clin Immunol 2007;119:881-91
48. Canonica GW, Bousquet J, Casale T, et al. Sub-lingual immunotherapy: World Allergy Organization position paper. Allergy 2009;64:1-59
49. Cox L, Jacobsen L. Comparison of allergen immunotherapy practice patterns in the United States and Europe. Ann Allergy Asthma Immunol 2009;103:451-60
50. Zuberbier T, Bachert C, Bousquet PJ, et al. GA2LEN/EAACI pocket guide for allergen-specific immunotherapy for allergic rhinitis and asthma. Allergy 2010;65:1525-30
51. Cox L, Nelson H, Lockey R, et al. Allergen immunotherapy: a practice parameter third update. J Allergy Clin Immunol 2011;127(Suppl):S1-55
52. Akdis M, Akdis C. Mechanisms of allergen-specific immunotherapy: multiple suppressor factors at work in immune tolerance to allergens. J Allergy Clin Immunol 2014;133:621-31
53. Moingeon P. Update on immune mechanisms associated with sublingual immunotherapy: practical implications for the clinician. J Allergy Clin Immunol Pract 2013;1:228-41
54. Frati F, Incorvaia C, David M, et al. Requirements for acquiring a high-quality house dust mite extract for allergen immunotherapy. Drug Design Dev Ther 2012;6:117-23
55. Moingeon P, Batard T, Nony E, et al. Quality control of House Dust Mite extracts for allergen immunotherapy. Int Arch Allergy Immunol 2013;161:285-6
56. Calderon MA, Simons FE, Malling HJ, et al. Sublingual allergen immunotherapy: mode of action and its relationship with the safety profile. Allergy 2012;67:302-11
57. Bernstein DI, Epstein T, Murphy-Berendts K, Liss GM. Surveillance of systemic reactions to subcutaneous immunotherapy injections: year 1 outcomes of the ACAAI and AAAAI collaborative study. Ann Allergy Asthma Immunol 2010;104:530-5
58. James LK, Shamji MH, Walker SM, et al. Long term tolerance after allergen immunotherapy is accompanied by selective persistence of blocking antibodies. J Allergy Clin Immunol 2011;127:509-16
59. Vanbervliet B, Tourdot S, Rouzaire P, et al. SLIT prevents the development of Eczema in percutaneous allergen-sensitized mice. J Invest Dermatol 2012;132:244-6
60. Fernandez-Caldas E. Towards a more complete standardization of mite allergen extracts. Int Arch Allergy Immunol 2013;160:1-3
61. Brunetto B, Tinghino R, Braschi MC, et al. Characterization and comparison of commercially available mite extracts for in vivo diagnosis. Allergy 2010;65:184-90
62. Casset A, Mari A, Purohit A, et al. Varying allergen composition and content affects the in vivo allergenic activity of commercial Dermatophagoides pteronyssinus extracts. Int Arch Allergy Immunol 2012;159:253-62
63. Moingeon P. Sublingual immunotherapy: from biological extracts to recombinant allergens. Allergy 2006;61(S81):15-19
64. Valenta R, Niespodziana K, Focke-Tejkl M, et al. Recombinant allergens: what does the future hold? J Allergy Clin Immunol 2011;127:860-4
65. Cromwell O, Hafner D, Nandy A. Recombinant allergens for specific immunotherapy. J Allergy Clin Immunol 2011;127:865-72
66. Campbell JD, Buckland KF, Mc Millan SJ, et al. peptide immunotherapy in allergic asthma generaltes IL-10-dependent immunological tolerance associated with linked epitope suppression. J Exp Med 2009;206:1535-47
67. Yang L, Kajiura H, Suzuki K, et al. Generation of a transgenic rice seed-based edible vaccine against house dust mite allergy. Biochem Biophys Res Commun 2008;365:334-9
68. Walgraffe D, Matteotti C, el Bakkoury M, et al. A hypoallergenic variant of Der p 1 as a candidate for mite allergy vaccines. J Allergy Clin Immunol 2009;123:1150-6
69. Burtin D, Chabre H, Didierlaurent A, et al. Production of native and modified recombinant Der p 1 forms in tobacco plants. Clin Exp Allergy 2009;39:760-70
70. Bussières L, Bordas V, Bulder I, et al. Fusion proteins assembling Der p 1 and Der p 2 major allergens from Dermatophagoides pteronyssinus. Int Arch Allergy Immunol 2010;153:141-51
71. Bordas V, Bussières L, Airouche S, et al. Expression and characterization of natural-like recombinant Der p 2 for sublingual immunotherapy. Int Arch Allergy Immunol 2012;158:157-67
72. Marth K, Focke-Teijkl M, Lupinek C, et al. Allergen peptides, recombinant allergens and hypoallergens for allergen-specific immunotherapy. Curr Treat Options Allergy 2014;1:91-106
73. Calamita Z, Saconato H, Pela AB, Atallah AN. Efficacy of sublingual immunotherapy in asthma: systematic review of randomized clinical trials using the cochrane collaboration method. Allergy 2006;61:1162-72
74. Penagos M, Passalacqua G, Compalati E, et al. Metaanalysis of the efficacy of sublingual immunotherapy in the treatment of allergic asthma in pediatric patients, 3 to 18 years of age. Chest 2008;133:599-609
75. Compalati E, Passalacqua G, Bonini M and Canonca GW. The efficacy of sublingual immunotherapy for house dust mites respiratory allergy: results of a GA2LEN meta-analysis. Allergy 2009;64:1570-9
76. Lin SY, Erekosima N, Kim JM, et al. Sublingual immunotherapy for the treatment of allergic rhinoconjunctivitis and asthma: a systematic review. JAMA 2013;309:1278-88
77. Abramson MJ, Puy RM, Weiner JM. Injection immunotherapy for asthma. Cochrane Data base Syst Rev 2010;8:CD001186
78. Calderon MA, Casale TB, Nelson HS, Demoly P. An evidence-based analysis of house dust mite allergen immunotherapy: a call for more rigorous clinical studies. J Allergy Clin Immunol 2013;132:1322-36
79. Ameal A, Vega-Chicote JM, Fernandez S, et al. Double blind and placebo-controlled study to assess efficacy and safety of a modified extract of Dermatophagoides pteronyssinus in allergic asthma. Allergy 2005;60:1178-83
80. Garcia-Robaina JC, de la Torre F, Sanchez I, et al. Successful management of mite-allergic asthma with modified extracts of Dermatophagoides pteronyssinus and Dermatophagoides farinae in a double-blind, placebo-controlled study. J Allergy Clin Immunol 2006;118:1026-32
81. Bergmann KC, Demoly P, Worm M, et al. Efficacy and safety of sublingual tablets of house dust mite allergen extracts in adults with allergic rhinitis. J Allergy Clin Immunol 2014;133:1608-14
82. Mosbech H, Deckelmann R, de Blay F, et al. Standardized quality (SQ) house dust mite sublingual immunotherapy tablet (ALK) reduces inhaled corticosteroid use while maintaining asthma control: a randomized, double blind, placebo-controlled trial. J Allergy Clin Immunol 2014;In Press
83. Larché M, Hickey P, Hebert J, Hafner R. Safety and tolerability of escalating doses of house dust mite-peptide antigen desensitization (HDM-PAD). abstract J Allergy Clin Immunol 2013;131:AB37
84. Kunding TM, Senti G, Schnetzler G, et al. Der p 1 peptide on virus-like particles is safe and highly immunogenic in healthy adults. J Allergy Clin Immunol 2006;117:1470-6
85. Chabre H, Gouyon B, Adam A, et al. Molecular variability of group 1 and 5 gras pollen allergens between Pooideae species: implications for specific immunotherapy. Clin Exp Allergy 2010;40:505-19
86. Moingeon P. The specificities of allergen recognition by CD4+ T lymphocytes at the epitopic level. Clin Exp Allergy 2014;44:898-900
87. Archila LD, DeLong JH, Wambre E, et al. Grass-specific CD4+ T cells exhibit varying degrees of cross-reactivity, implications for allergen-specific immunotherapy. Clin Exp Allergy 2014;44:986-98
88. Wambre E, Delong JH, James EA, et al. Specific immunotherapy modifies allergen-specific CD4+ T cell responses in an epitope-dependent manner. J Allergy Clin Immunol 2013;133:872-9